Bausch Health's Cirrhosis Pathway Pilot Shows Modest Gains in Care Adherence
Event summary
- Six-month pilot study across five community gastroenterology practices improved adherence to cirrhosis care guidelines by 3.2% to 9.4% across five key metrics.
- Study leveraged Cardinal Health's PPS Analytics platform to monitor and optimize care pathways.
- Results to be presented at the American College of Gastroenterology Annual Scientific Meeting (October 9-14, 2026).
- 4,251 patients with cirrhosis included in the analysis.
The big picture
Bausch Health's pilot study addresses the persistent variability in cirrhosis care across community settings, a critical issue as liver disease prevalence grows. The results suggest that standardized pathways supported by analytics can improve guideline adherence, potentially reducing morbidity and healthcare utilization. This aligns with broader industry trends toward value-based care and data-driven clinical decision-making.
What we're watching
- Scalability Challenge
- Whether Bausch Health can expand this pilot model beyond the initial five practices and maintain effectiveness at scale.
- Regulatory Validation
- The pace at which peer-reviewed validation of these findings will influence broader adoption in community gastroenterology settings.
- Competitive Differentiation
- How this pathway innovation positions Salix Pharmaceuticals against competitors in the cirrhosis management space.